Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELUMEN: Everolimus and 177Lu-DOTATATE in Refractory Meningioma
NCT06126588Phase 2Recruiting
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in meningioma, sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Response Assessment in Neuro-Oncology criteria at 7 months. Started Nov 2024; status: recruiting.
02
Drugs
everolimus
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06126588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126588.